{"entity":{"id":"hb0036","kind":"drug","name":"HB0036","aka":["Anti-PD-L1 and anti-TIGIT bifunctional molecule"],"tldr":"HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.","summary":"HB0036 is an investigational agent whose form is not stated in the registry developed by Shanghai Huaota Biopharmaceutical. Its targets are PD-L1 and TIGIT (the sponsor names PD-L1 x TIGIT). The sponsor states: HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways. ClinicalTrials.gov describes the intervention as: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05417321, plans to enrol 80 participants with primary completion was scheduled for 2025-08-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of HB0036","url":"https://clinicaltrials.gov/search?intr=HB0036"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pdl1","tigit"],"drugs":[],"companies":["huabo-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05417321"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)","mechanism":"HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hb0036/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"company":[{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","route":"/companies/huabo-biopharm/"}],"trial":[{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","route":"/trials/nct05417321/"}]}}